Cavallari Larisa H, Perera Minoli A
Department of Pharmacy Practice, University of Illinois at Chicago, College of Pharmacy, 833 South Wood Street, Chicago, IL 60612-7230, USA.
Future Cardiol. 2012 Jul;8(4):563-76. doi: 10.2217/fca.12.31.
Genotype-based dosing recommendations are provided in the US FDA-approved warfarin labeling. However, data that informed these recommendations were from predominately Caucasian populations. Studies show that variants contributing to warfarin dose requirements in Caucasians provide similar contributions to dose requirements in US Hispanics, but significantly lesser contributions in African-Americans. Further data demonstrate that variants occurring commonly in individuals of African ancestry, but rarely in other racial groups, significantly influence dose requirements in African-Americans. These data suggest that it is important to consider variants specific for African-Americans when implementing genotype-guided warfarin dosing in this population.
美国食品药品监督管理局（FDA）批准的华法林标签中提供了基于基因型的给药建议。然而，形成这些建议的数据主要来自白种人群体。研究表明，影响白种人对华法林剂量需求的基因变异，对美国西班牙裔人群的剂量需求也有类似影响，但对非裔美国人的剂量需求影响明显较小。进一步的数据表明，常见于非洲裔个体但很少见于其他种族群体的基因变异，显著影响非裔美国人的剂量需求。这些数据表明，在该人群中实施基因型指导的华法林给药时，考虑非裔美国人特有的基因变异非常重要。
